Navigation Links
Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix(R)) Non-Responders
Date:11/12/2008

- Direct-Acting PRT060128 Provides Reversible, High-level Platelet

Inhibition with Immediate Onset of Action -

NEW ORLEANS and SOUTH SAN FRANCISCO, Calif., Nov. 12 /PRNewswire/ -- Portola Pharmaceuticals, a biopharmaceutical company developing innovative drugs that provide significant advances in cardiovascular and inflammatory diseases, and cancer, today announced new clinical data that demonstrate PRT060128, the Company's novel anti-platelet drug that directly and reversibly inhibits the P2Y12 ADP receptor, overcomes high platelet reactivity (HPR) in patients who do not respond to clopidogrel (Plavix(R)). The results [Abstract #5603] were presented at the American Heart Association (AHA) Scientific Sessions 2008 in New Orleans, LA.

Studies show there is substantial variability in patient response to clopidogrel therapy with up to 30% of patients not responding to treatment. Numerous studies link this suboptimal treatment response to poor clinical outcomes.

PRT060128 is the only reversible, direct acting, intravenous (IV) and oral ADP receptor antagonist in clinical development. Inhibiting the P2Y12 ADP receptor on platelets has been proven to prevent thrombosis and subsequent heart attacks. Portola believes that PRT060128 may provide significant clinical benefit through immediate, high-level platelet inhibition in the acute setting and a seamless transition to predictable, reversible platelet inhibition in the chronic setting.

"Of the millions of cardiac patients treated with clopidogrel anti- platelet therapy every year, a significant portion do not respond, and remain at high risk for major adverse cardiac events," said Paul A. Gurbel, M.D., principal investigator and Director of Cardiovascular Research at the Center for Thrombosis Research at Sinai Hospital, Baltimore, MD. "These results show that this direct-acting anti-platelet agent with a novel mechanism of action may have the potential to fill this sign
'/>"/>

SOURCE Portola Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
2. Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
3. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
4. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
5. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
6. Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring
7. Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test
8. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
9. Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
10. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
11. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... SHANGHAI , July 29, 2015 WuXi ... open-access R&D capability and technology platform company serving the ... China and the ... release financial results for the second-quarter of 2015 after ... 13, 2015 (which will be Friday morning, August 14, ...
(Date:7/29/2015)... 29, 2015  Depomed, Inc. (NASDAQ: DEPO ) ... Board of Directors, after careful consideration and with ... advisors, has unanimously rejected the purported revised, highly ... plc (NASDAQ: HZNP ) ("Horizon") to acquire ... an all-stock transaction (the "July 21 Proposal"). ...
(Date:7/29/2015)... Washington , 29 luglio 2015 ... ha scoperto che l,ingestione quotidiana del probiotico ... intestinale umano e modifica la produzione intestinale di ... studio riguardava la somministrazione quotidiana di ceppo di ... SD-5865) in compresse utilizzando il sistema di somministrazione ...
Breaking Medicine Technology:WuXi PharmaTech Schedules Second-Quarter 2015 Earnings Release 2Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 2Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 3Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 4Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 5Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 6Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 7Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 8Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 9È stato clinicamente dimostrato che il probiotico L. reuteri di Nutraceutix regola il metabolismo insulinico intestinale 2
... Dec. 8, 2011  RainTree Oncology Services (RainTree Oncology), ... and management services, today announced it has signed ... the nation,s largest privately-owned specialty pharmacy providing medication ... the Company to provide community oncology practices with ...
... 2011   Leatt Corporation (OTC: LEAT.PK), a global ... brace system designed to help prevent potentially devastating injuries ... today that the 2011 Annual Meeting (Meeting) of its ... Thursday, December 22, 2011.  Stockholders of record as of ...
Cached Medicine Technology:RainTree Oncology Services Announces Service Agreement With Diplomat Specialty Pharmacy 2RainTree Oncology Services Announces Service Agreement With Diplomat Specialty Pharmacy 3Leatt Corporation Announces 2011 Annual Shareholders' Meeting 2
(Date:7/29/2015)... , ... July 29, 2015 , ... Andrzej Klos, M.D., ... Klos, a board-certified pediatrician for nearly 38 years, is motivated each and every day ... commitment to his profession shine alongside his many awards and accolades, which include multiple ...
(Date:7/29/2015)... Washington, D.C. (PRWEB) , ... July 29, 2015 ... ... released a white paper, Our Best Shot: Expanding Prevention through Vaccination in ... underutilization in seniors and offers recommendations on how industry, government, and health care ...
(Date:7/29/2015)... ... 2015 , ... " Core Organizer ” was featured on NewsWatch as part ... on the market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch ... will help anyone get organized. , Wouldn’t it be great if everyone could be ...
(Date:7/29/2015)... ... ... Angelo’s FabriClean, an area rug cleaning company in South Surrey, has recently ... The company will now reverse the damage caused by water on carpets for homes ... rain leaking through an accidently left open window or a broken underground pipeline can ...
(Date:7/29/2015)... Dallas, TX (PRWEB) , ... July 29, 2015 ... ... provides comprehensive information on the therapeutic development for Atherosclerosis. Atherosclerosis is a slow, ... identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, Dr. Andrzej Klos of Carepoint Health Pediatrics! 2Health News:NJ Top Docs Presents, Dr. Andrzej Klos of Carepoint Health Pediatrics! 3Health News:Vaccination Rates in Older Adults Fall Short of Targets 2Health News:Vaccination Rates in Older Adults Fall Short of Targets 3Health News:Get More Organized with the Core Organizer App 2Health News:Angelo’s FabriClean Now Offers Water Damage Restoration For Residential and Commercial Accounts 2Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4
... report shows, , TUESDAY, March 2 (HealthDay News) -- ... new government study shows, but certain states have significantly ... rate of asthma is currently estimated to be 7.85 ... percent every three years. But, the report also found ...
... , ... ... ... ...
... ... ... ... ...
... , ... ... , ... , , ...
... ... focusing on insights into the exploding field of neuroscience, what this means for leadership ... most effective ways to motivate and generate transformation in organisations – all leading to ... ...
... ... to qualified Independent Software Developers. , ... RSA San Francisco, CA (PRWEB) March 2, 2010 ... (CA) and specialists in supplying Digital Identities used to authenticate the publisher of ...
Cached Medicine News:Health News:Asthma Rates Rising Across the U.S. 2Health News:Asthma Rates Rising Across the U.S. 3Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 2Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 3Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 4Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 5Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 6Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 7Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 8Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 9Health News:ReportsandReports : The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies 2Health News:ReportsandReports : The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies 3Health News:ReportsandReports : The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies 4Health News:ReportsandReports : The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies 5Health News:ReportsandReports : The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies 6Health News:ReportsandReports : The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies 7Health News:InterAmerican College Announces Certification of Master of Science in Nursing - Family Nurse Practitioner Program 2Health News:InterAmerican College Announces Certification of Master of Science in Nursing - Family Nurse Practitioner Program 3Health News:Key Leadership Seminar: Maximizing Profit through Social Intelligence - What Neuroscience Tells Us 2Health News:GlobalSign Releases Code Signing Certificates for Individual Software Developers 2Health News:GlobalSign Releases Code Signing Certificates for Individual Software Developers 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: